Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection

J Infect Dis. 2003 Sep 15;188(6):864-72. doi: 10.1086/377105. Epub 2003 Sep 4.

Abstract

In approximately half of human immunodeficiency virus (HIV) type 1-infected individuals, the development of CXC chemokine receptor 4-using, syncytium-inducing (SI) virus variants precedes a rapid progression to acquired immunodeficiency syndrome (AIDS). In other individuals, only CC chemokine receptor 5-using (R5), non-SI (NSI) virus variants are present throughout infection. These individuals may be either long-term survivors (LTSs) or rapid progressors. The basis for this variable disease progression in individuals with only R5 virus variants is not yet fully understood. In this study, the beta-chemokine sensitivity of biological HIV-1 clones isolated from 13 individuals who harbored only R5, NSI virus variants (7 LTSs and 6 progressors) was investigated. We found a statistically significant decrease in sensitivity of virus variants to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization during the course of progressive infection, but not during follow-up of LTSs. Our data suggest that a role exists for RANTES neutralization sensitivity of HIV-1 in AIDS pathogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chemokine CCL5 / immunology*
  • Disease Progression
  • Genetic Variation*
  • Genotype
  • Giant Cells / physiology
  • HIV Infections / immunology*
  • HIV Infections / physiopathology
  • HIV Infections / virology
  • HIV Long-Term Survivors*
  • HIV-1 / classification
  • HIV-1 / genetics
  • HIV-1 / immunology*
  • HIV-1 / pathogenicity
  • Humans
  • Neutralization Tests
  • Receptors, CCR5 / metabolism*

Substances

  • Chemokine CCL5
  • Receptors, CCR5